Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

QBQaiser BashirGCGeorge ChenWFWarren Fingrut

Discussion

Loading...

Member takes

Overview

Phase 2 trial improved progression-free survival in high-risk AML patients using cladribine, thiotepa, and venetoclax, highlighting efficacy in TP53 mutation cases.

Key Points

  • Median progression-free survival was 58% at three years, indicating effective treatment in high-risk acute myeloid leukemia patients.
  • The primary endpoint of progression-free survival showed notable results, particularly in patients with TP53 mutations and lower relapse rates.
  • This phase 2 trial utilized a novel conditioning regimen involving cladribine, thiotepa, venetoclax, and post-transplant cyclophosphamide.
  • These findings suggest that this myeloablative conditioning may offer a new approach for improving outcomes in high-risk AML patients.

Cite This Study

Bashir et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0cdhttps://doi.org/10.1182/blood-2025-378
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation2025
  2. 2Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis2025
  3. 3Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.2025 · 1 citations
  4. 4Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  5. 5An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025